Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$38.65 - $43.48 $289,875 - $326,100
-7,500 Reduced 50.34%
7,400 $296,000
Q1 2024

May 15, 2024

BUY
$42.85 - $63.45 $154,260 - $228,420
3,600 Added 31.86%
14,900 $654,000
Q4 2023

Feb 14, 2024

BUY
$44.49 - $62.93 $93,429 - $132,153
2,100 Added 22.83%
11,300 $698,000
Q3 2023

Nov 14, 2023

BUY
$45.51 - $65.0 $104,673 - $149,500
2,300 Added 33.33%
9,200 $423,000
Q2 2023

Aug 14, 2023

BUY
$35.77 - $58.38 $42,924 - $70,056
1,200 Added 21.05%
6,900 $396,000
Q1 2023

May 15, 2023

SELL
$27.99 - $37.92 $67,176 - $91,008
-2,400 Reduced 29.63%
5,700 $213,000
Q4 2022

Feb 14, 2023

SELL
$27.93 - $31.27 $365,883 - $409,637
-13,100 Reduced 61.79%
8,100 $226,000
Q3 2022

Nov 14, 2022

SELL
$27.56 - $37.75 $336,232 - $460,550
-12,200 Reduced 36.53%
21,200 $596,000

Others Institutions Holding AMPH

About Amphastar Pharmaceuticals, Inc.


  • Ticker AMPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,015,200
  • Market Cap $2.34B
  • Description
  • Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-count...
More about AMPH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.